Personalis, Inc. reposted this
We're ready to welcome our members at Personalis, Inc. for our Q3 meeting!
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California.
External link for Personalis, Inc.
6600 Dumbarton Circle
Fremont, California 94555, US
Personalis, Inc. reposted this
We're ready to welcome our members at Personalis, Inc. for our Q3 meeting!
We’re in Boston this week for World CB & CDx. If you’re in town for the event, drop by our booth # 25! Don’t forget to check out a presentation by Travis Yates, PhD, Senior Field Applications Scientist, at Personalis on September 5th at 4:10PM EDT highlighting various impactful studies utilizing NeXT Personal® in early-stage lung and breast cancer. #PrecisionOncology #Biomarkers #MRD #ctDNA #WorldCDx
We’re excited to be hosting the BLOODPAC Q3 meeting next week! We look forward to seeing you there. #LiquidBiopsy #PrecisionOncology
We’re excited to be exhibiting at the 2024 Annual ESMO Congress in Barcelona, Spain in September! Stop by our booth # 509 at #ESMO24 to learn more about our advanced solutions for oncology, including our ultra-sensitive minimal residual disease (MRD) platform, NeXT Personal®. Make sure to check out our podium and poster presentations listed below. #PrecisionOncology #TRACERx #LungCancer #Biomarkers #ctDNA #ImmunoTherapy
Personalis, Inc. reposted this
🎉 Just 7 days to go! 🎉 BLOODPAC’s third quarter meeting is right around the corner! Join us in just one week on September 4th and 5th in Fremont, California, hosted by @PersonalisInc. We’re so excited to see everyone there! 🚀 #BLOODPACQ3 #OneWeekOut
We’re excited to be at World CB & CDx next week in Boston! Visit us at booth # 25 to learn more about our flagship ultra-sensitive minimal residual disease (MRD) platform, NeXT Personal®. Make sure to check out a presentation by Travis Yates, PhD, Senior Field Applications Scientist, at Personalis. Dr. Yates will cover several impactful studies utilizing NeXT Personal in early-stage lung and breast cancer and explore the implications of using an ultra-sensitive MRD detection assay in these indications. #PrecisionOncology #Biomarkers #LiquidBiopsy #MRD #ctDNA #WorldCDx
Personalis, Inc. reposted this
📢 ClearNote Health will be at the 14th World CB & CDx Boston Summit from September 3rd to 6th. 📍 Find us at #Booth35 and learn more about the advantages of the Virtuoso Epigenomics Platform, our liquid based monitoring tools and the power of longitudinal analysis in your translational research program. Virtuoso empowers more efficient and effective drug development by providing insights into disease biology, therapy response, and resistance - all from a simple blood draw. Reach out to schedule a meeting in advance! #CDx #drugdevelopment #therapyresponse
ICYMI: Earlier this month, we announced the expansion of our commercial relationship with Tempus AI. Tempus is the exclusive commercial partner for Personalis’ ultra-sensitive tumor-informed minimal residual disease (MRD) product for breast and lung cancers, and for immunotherapy monitoring across all solid tumors. Following exceptionally strong demand, both companies have agreed to accelerate commercialization efforts, including Tempus investing a total of approximately $36 million into Personalis among other key terms. Learn more from the GenomeWeb article: https://bit.ly/3X8GqV4 #PrecisionOncology #LiquidBiopsy #LungCancer #BreastCancer #Immunotherapy #MRDTesting
BLOODPAC's Q3 Meeting is fast approaching, and Personalis is honored to be hosting, as we bring together industry leaders to accelerate the development, validation and accessibility of liquid biopsy assays to improve the outcomes of patients with cancer. Join us in Silicon Valley for two days of innovation and collaboration. #LiquidBiopsy #PrecisionOncology
“Highly sensitive MRD tests like NeXT Personal® will open up even more opportunities to use MRD testing in a broader set of cancer types and stages,” says Dr. Richard Chen, Chief Medical Officer and EVP of R&D at Personalis in this article for Biocompare. Ultra-sensitivity is required from next-generation sequencing based minimal residual disease (MRD) tests to detect cancer recurrence early. Ultra-sensitivity has the power to deliver more trust in the negative MRD result. NeXT Personal is an ultra-sensitive and specific MRD test, which has been shown to detect early-stage lung and breast cancer recurrence months prior to disease being visible on scans. Discover more from the article: https://bit.ly/3yJdivi. #PrecisionOncology #LiquidBiopsy #NGS #MRD #ctDNA